Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management

Abstract Type 2 diabetes is one of the most relevant risk factors for heart failure, the prevalence of which is increasing worldwide. The aim of the review is to highlight the current perspectives of the pathophysiology of heart failure as it pertains to type 2 diabetes. This review summarizes the p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonio Ceriello, Doina Catrinoiu, Chanchal Chandramouli, Francesco Cosentino, Annique Cornelia Dombrowsky, Baruch Itzhak, Nebojsa Malić Lalic, Francesco Prattichizzo, Oliver Schnell, Petar M. Seferović, Paul Valensi, Eberhard Standl, the D&CVD EASD Study Group
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Type 2 diabetes Heart failure NT-proBNP Guidelines Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/6ee10ae5c6a8410c838a03995dffc4c6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6ee10ae5c6a8410c838a03995dffc4c6
record_format	dspace
spelling	oai:doaj.org-article:6ee10ae5c6a8410c838a03995dffc4c62021-11-08T10:45:12ZHeart failure in type 2 diabetes: current perspectives on screening, diagnosis and management10.1186/s12933-021-01408-11475-2840https://doaj.org/article/6ee10ae5c6a8410c838a03995dffc4c62021-11-01T00:00:00Zhttps://doi.org/10.1186/s12933-021-01408-1https://doaj.org/toc/1475-2840Abstract Type 2 diabetes is one of the most relevant risk factors for heart failure, the prevalence of which is increasing worldwide. The aim of the review is to highlight the current perspectives of the pathophysiology of heart failure as it pertains to type 2 diabetes. This review summarizes the proposed mechanistic bases, explaining the myocardial damage induced by diabetes-related stressors and other risk factors, i.e., cardiomyopathy in type 2 diabetes. We highlight the complex pathology of individuals with type 2 diabetes, including the relationship with chronic kidney disease, metabolic alterations, and heart failure. We also discuss the current criteria used for heart failure diagnosis and the gold standard screening tools for individuals with type 2 diabetes. Currently approved pharmacological therapies with primary use in type 2 diabetes and heart failure, and the treatment-guiding role of NT-proBNP are also presented. Finally, the influence of the presence of type 2 diabetes as well as heart failure on COVID-19 severity is briefly discussed.Antonio CerielloDoina CatrinoiuChanchal ChandramouliFrancesco CosentinoAnnique Cornelia DombrowskyBaruch ItzhakNebojsa Malić LalicFrancesco PrattichizzoOliver SchnellPetar M. SeferovićPaul ValensiEberhard Standlthe D&CVD EASD Study GroupBMCarticleType 2 diabetesHeart failureNT-proBNPGuidelinesDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiovascular Diabetology, Vol 20, Iss 1, Pp 1-19 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Type 2 diabetes Heart failure NT-proBNP Guidelines Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Type 2 diabetes Heart failure NT-proBNP Guidelines Diseases of the circulatory (Cardiovascular) system RC666-701 Antonio Ceriello Doina Catrinoiu Chanchal Chandramouli Francesco Cosentino Annique Cornelia Dombrowsky Baruch Itzhak Nebojsa Malić Lalic Francesco Prattichizzo Oliver Schnell Petar M. Seferović Paul Valensi Eberhard Standl the D&CVD EASD Study Group Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
description	Abstract Type 2 diabetes is one of the most relevant risk factors for heart failure, the prevalence of which is increasing worldwide. The aim of the review is to highlight the current perspectives of the pathophysiology of heart failure as it pertains to type 2 diabetes. This review summarizes the proposed mechanistic bases, explaining the myocardial damage induced by diabetes-related stressors and other risk factors, i.e., cardiomyopathy in type 2 diabetes. We highlight the complex pathology of individuals with type 2 diabetes, including the relationship with chronic kidney disease, metabolic alterations, and heart failure. We also discuss the current criteria used for heart failure diagnosis and the gold standard screening tools for individuals with type 2 diabetes. Currently approved pharmacological therapies with primary use in type 2 diabetes and heart failure, and the treatment-guiding role of NT-proBNP are also presented. Finally, the influence of the presence of type 2 diabetes as well as heart failure on COVID-19 severity is briefly discussed.
format	article
author	Antonio Ceriello Doina Catrinoiu Chanchal Chandramouli Francesco Cosentino Annique Cornelia Dombrowsky Baruch Itzhak Nebojsa Malić Lalic Francesco Prattichizzo Oliver Schnell Petar M. Seferović Paul Valensi Eberhard Standl the D&CVD EASD Study Group
author_facet	Antonio Ceriello Doina Catrinoiu Chanchal Chandramouli Francesco Cosentino Annique Cornelia Dombrowsky Baruch Itzhak Nebojsa Malić Lalic Francesco Prattichizzo Oliver Schnell Petar M. Seferović Paul Valensi Eberhard Standl the D&CVD EASD Study Group
author_sort	Antonio Ceriello
title	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
title_short	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
title_full	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
title_fullStr	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
title_full_unstemmed	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
title_sort	heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
publisher	BMC
publishDate	2021
url	https://doaj.org/article/6ee10ae5c6a8410c838a03995dffc4c6
work_keys_str_mv	AT antonioceriello heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT doinacatrinoiu heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT chanchalchandramouli heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT francescocosentino heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT anniquecorneliadombrowsky heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT baruchitzhak heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT nebojsamaliclalic heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT francescoprattichizzo heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT oliverschnell heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT petarmseferovic heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT paulvalensi heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT eberhardstandl heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement AT thedcvdeasdstudygroup heartfailureintype2diabetescurrentperspectivesonscreeningdiagnosisandmanagement
_version_	1718442626288451584

Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management

Ejemplares similares